Page 186 - FINAL PROGRAM

P-735 Comparing the inter-cycle variation of serum anti-Mullerian hormone and antral follicle count measurements in predicting ovarian response before IVF
H.W.R. Li (Hong Kong)
P-736 Intracellular oxidative stress in granulose cells impact on ART success in reduced ovarian reserve
M. Santonastaso (Italy)
P-737 Reproductive outcomes in patients with polycystic ovaries: does phenotype matter?
S. Pareyn (Belgium)
P-738 How to implement in real-life settings the results of meta analysis? Example of dydrogesterone as luteal phase support after fresh embryo transfer in IVF procedure N. Massin (France)
P-739 De ning critical progesterone elevation to estimate effect on pregnancy and live birth rates: in uence of selected threshold on exposure frequency, effect size and clinical impact.
M. Caballero (Spain)
P-740 The most effective starting dose of gonadotropins in the rst IVF cycle in patients under 35 years of age - GnRH agonist versus antagonist protocol.
P. Kuć (Poland)
P-741 Anti-Müllerian hormone (AMH) serum levels enable preoperative estimation of the number of cumulus-oocyte complexes (COC) in female-to-male transgender persons (trans men) C. De Roo (Belgium)
P-742 Start stop protocol: A preliminary study of a new controlled ovarian stimulation method for Bologna poor responders
B. Yilmaz (Turkey)
P-743 Long-term health of women with FSH resistant ovaries
K. Luiro-Helve (Finland)
P-744 Different pregnancy rate with the same results of AMH using 5 different AMH kits including new automated assays
D. Bialobrzeska-Lukaszuk (Poland)
P-745 Serum Prolactin and Cortisol levels for luteal phase support (LPS) during IVF: subcutaneous vs intramuscolar progesterone
F. Caprio (Italy)
P-746 Serum vitamin D is not associated with ovarian reserve in infertile patients
B.C. Tarlatzis (Greece)
P-747 Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for controlled ovarian stimulation in IVF/ICSI cycles
M.H. Mochtar (The Netherlands)
182